guest ::
| Home > Publications database > Dimethyl fumarate (DMF) therapy in CTCL: results from a clinical phase II study. > print |
| Home > Publications database > Dimethyl fumarate (DMF) therapy in CTCL: results from a clinical phase II study. > print |
| 001 | 177072 | ||
| 005 | 20240229133730.0 | ||
| 024 | 7 | _ | |a 10.1016/S0959-8049(21)00666-3 |2 doi |
| 024 | 7 | _ | |a pmid:34649646 |2 pmid |
| 024 | 7 | _ | |a 0014-2964 |2 ISSN |
| 024 | 7 | _ | |a 0959-8049 |2 ISSN |
| 024 | 7 | _ | |a 1879-0852 |2 ISSN |
| 024 | 7 | _ | |a (1990) |2 ISSN |
| 024 | 7 | _ | |a 1879-2995 |2 ISSN |
| 024 | 7 | _ | |a (1965) |2 ISSN |
| 037 | _ | _ | |a DKFZ-2021-02278 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Nicolay, Jan |0 P:(DE-He78)7b847bc226706f4fc5a573f1483c49d9 |b 0 |e First author |u dkfz |
| 245 | _ | _ | |a Dimethyl fumarate (DMF) therapy in CTCL: results from a clinical phase II study. |
| 260 | _ | _ | |a Amsterdam [u.a.] |c 2021 |b Elsevier |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1634555760_21234 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a #EA:A370#LA:D030# |
| 536 | _ | _ | |a 314 - Immunologie und Krebs (POF4-314) |0 G:(DE-HGF)POF4-314 |c POF4-314 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de |
| 650 | _ | 7 | |a CTCL |2 Other |
| 650 | _ | 7 | |a NFκB |2 Other |
| 650 | _ | 7 | |a apoptosis |2 Other |
| 650 | _ | 7 | |a clinical study |2 Other |
| 650 | _ | 7 | |a targeted therapy |2 Other |
| 700 | 1 | _ | |a Albrecht, Jana D |0 P:(DE-HGF)0 |b 1 |
| 700 | 1 | _ | |a Assaf, Chalid |b 2 |
| 700 | 1 | _ | |a Dippel, Edgar |b 3 |
| 700 | 1 | _ | |a Stadler, Rudolf |b 4 |
| 700 | 1 | _ | |a Wehkamp, Ulrike |b 5 |
| 700 | 1 | _ | |a Wobser, Marion |b 6 |
| 700 | 1 | _ | |a Guelow, Karsten |b 7 |
| 700 | 1 | _ | |a Goerdt, Sergij |b 8 |
| 700 | 1 | _ | |a Krammer, Peter |0 P:(DE-He78)92492c6eae05ee58973fc142c9201e3d |b 9 |e Last author |
| 773 | _ | _ | |a 10.1016/S0959-8049(21)00666-3 |g Vol. 156 Suppl 1, p. S21 - S22 |0 PERI:(DE-600)1468190-0 |p S21 - S22 |t European journal of cancer |v 156 Suppl 1 |y 2021 |x 0959-8049 |
| 909 | C | O | |o oai:inrepo02.dkfz.de:177072 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 0 |6 P:(DE-He78)7b847bc226706f4fc5a573f1483c49d9 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 1 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 9 |6 P:(DE-He78)92492c6eae05ee58973fc142c9201e3d |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-314 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Immunologie und Krebs |x 0 |
| 914 | 1 | _ | |y 2021 |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |d 2021-01-28 |w ger |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2021-01-28 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2021-01-28 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2021-01-28 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2021-01-28 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2021-01-28 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2021-01-28 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2021-01-28 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2021-01-28 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2021-01-28 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2021-01-28 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b EUR J CANCER : 2019 |d 2021-01-28 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2021-01-28 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2021-01-28 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b EUR J CANCER : 2019 |d 2021-01-28 |
| 920 | 1 | _ | |0 I:(DE-He78)A370-20160331 |k A370 |l KKE Dermatoonkologie |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)D030-20160331 |k D030 |l Immungenetik |x 1 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)A370-20160331 |
| 980 | _ | _ | |a I:(DE-He78)D030-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|